PHILADELPHIA, PA — Carlos Medina had already made peace with the surgery. His thoracic oncologist at a major academic center had outlined the plan: extrapleural pneumonectomy, followed by chemotherapy, followed by radiation. It was the protocol his team had used for years. Then, in early 2025, a second opinion changed everything. A different specialist suggested trying nivolumab and ipilimumab first, before any knife touched his chest. Medina, a 61-year-old former shipyard insulator from Delaware, agreed. Fourteen months later, his tumor had shrunk enough that a less aggressive lung-sparing surgery became possible.
Medina's case isn't an outlier anymore. Across the country's leading mesothelioma centers, oncologists are actively debating a question that would have seemed almost heretical a decade ago: should immunotherapy come before surgery, not after? The answer is reshaping treatment planning for thousands of patients, and the data behind it is accumulating fast.
What's Driving the Shift in Treatment Sequencing?
The reconsideration of treatment order for malignant pleural mesothelioma stems from a convergence of two developments: improved surgical outcomes data and the FDA's 2020 approval of nivolumab plus ipilimumab for unresectable malignant pleural mesothelioma. According to the FDA, the CheckMate 743 trial demonstrated that the combination immunotherapy regimen improved overall survival compared to platinum-based chemotherapy, marking the first new first-line approval for the disease in more than 15 years. That approval gave oncologists a powerful new tool, but it also raised an immediate question: where does it fit in the treatment sequence for patients who are surgical candidates?
For decades, the standard approach for eligible patients was surgery first, typically extrapleural pneumonectomy (EPP), followed by adjuvant chemotherapy. But a growing body of comparative outcomes research has complicated the picture. A systematic review and meta-analysis published in a peer-reviewed oncology journal found that pleurectomy and decortication, a lung-sparing alternative to EPP, carried significantly lower perioperative mortality while achieving comparable survival outcomes in appropriately selected patients. That finding, combined with the immunotherapy data, has pushed specialists toward a more flexible, individualized approach.
From an occupational health perspective, the patients most affected by this debate are the ones with the longest and heaviest asbestos exposure histories. Workers in these industries, including shipbuilding, insulation installation, and industrial pipe fitting, often develop mesothelioma with extensive pleural involvement, precisely the cases where surgical eligibility is most in question and where neoadjuvant immunotherapy might shrink tumors enough to make surgery viable.
Why the Surgical Decision Is More Complicated Than It Looks
Choose the wrong surgery at the wrong time, and you may close off better options permanently. That's the quiet concern driving much of this recalibration.
The debate between EPP and pleurectomy/decortication has been one of the most contentious in mesothelioma surgery for years. EPP removes the entire affected lung along with the pleura, diaphragm, and pericardium. P/D preserves the lung while removing the tumor-laden pleural lining. According to research comparing outcomes across both procedures, P/D is associated with lower 30-day mortality, though EPP may offer better local control in select cases with extensive disease burden. A 2020 comparative analysis in the oncology literature found that P/D patients had perioperative mortality rates roughly half those of EPP patients, a finding that has increasingly shifted institutional preferences toward the lung-sparing approach.
But here's where immunotherapy complicates the calculus. Nivolumab and ipilimumab work by unleashing the immune system against tumor cells, a mechanism that, according to research published in the National Institutes of Health's PubMed Central database, can produce durable responses in a subset of mesothelioma patients. If a patient receives immunotherapy first and achieves significant tumor reduction, they may become eligible for P/D when EPP would have previously been the only surgical option. That's a meaningful quality-of-life difference. Losing a lung carries permanent functional consequences. Keeping it does not.
The Memorial Sloan Kettering Cancer Center, one of the country's highest-volume mesothelioma programs, has outlined a multidisciplinary evaluation process that considers performance status, disease extent, and histologic subtype before any surgical recommendation. According to MSKCC's published treatment approach, epithelioid histology, the most common mesothelioma subtype, tends to respond better to both surgery and immunotherapy than the sarcomatoid or biphasic variants.
For patients navigating these decisions, the patients and families resource hub on this site offers a detailed breakdown of what to expect at each stage of the treatment planning process.
What the Immunotherapy Data Actually Shows
What the exposure data reveals about mesothelioma's biological behavior is this: it's not a disease that responds uniformly to any single approach. That variability is exactly why the immunotherapy findings from CheckMate 743 were so significant.
The trial enrolled 605 patients with previously untreated unresectable malignant pleural mesothelioma. According to the FDA's approval documentation, patients receiving nivolumab plus ipilimumab had a median overall survival of 18.1 months compared to 14.1 months for those receiving pemetrexed-based chemotherapy. The benefit was most pronounced in non-epithelioid histology, where immunotherapy produced a 12-month survival rate of 57% versus 36% for chemotherapy. That's a substantial gap for a disease where median survival has historically been measured in months, not years.
The research published in NIH's PubMed Central reviewing immunotherapy advances for mesothelioma notes that checkpoint inhibitor combinations, particularly those targeting PD-1 and CTLA-4 pathways simultaneously, have produced the most durable responses in clinical settings. The dual blockade approach used in nivolumab/ipilimumab appears to overcome some of the immune evasion mechanisms that mesothelioma tumors are particularly adept at deploying.
For a deeper look at how these mechanisms work at the cellular level, the immunotherapy for mesothelioma encyclopedia entry provides a comprehensive explanation.
Bevacizumab, an anti-angiogenic agent that inhibits blood vessel formation in tumors, has also been studied as an addition to standard chemotherapy. Research examining bevacizumab in combination with pemetrexed and cisplatin found modest but statistically significant survival improvements, suggesting that multi-agent approaches targeting different tumor pathways may offer incremental gains for patients who aren't immunotherapy candidates.
MD Anderson Cancer Center's mesothelioma program, one of the largest in the country, has been actively studying how to integrate these agents into surgical pathways. Their published treatment framework emphasizes that patients should be evaluated by a multidisciplinary tumor board before any treatment decision is finalized, particularly for those with resectable disease.
!Physician's hands compare two treatment protocol documents on consultation table
How Does Peritoneal Mesothelioma Fit Into This Picture?
The surgical-immunotherapy debate looks different for the roughly 20 to 30 percent of mesothelioma patients who develop the peritoneal form of the disease, which affects the abdominal lining rather than the chest. For these patients, the standard of care has followed a distinct path.
Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy, known as HIPEC, has been the established treatment for eligible peritoneal mesothelioma patients for more than two decades. Research published in the Journal of Clinical Oncology examined outcomes for patients undergoing this combined approach and found median survival exceeding five years in patients who achieved complete cytoreduction, a result that remains among the most favorable in the entire mesothelioma treatment landscape.
The question now is whether immunotherapy has a role in peritoneal mesothelioma, either before HIPEC to reduce tumor burden or after surgery to prevent recurrence. Clinical trials are actively exploring this, though the evidence base is less mature than for pleural disease. What the exposure data reveals for peritoneal patients is that their occupational histories often mirror those of pleural patients, with heavy asbestos exposure in industrial and construction settings driving the majority of cases.
Veterans deserve special mention here. The Department of Veterans Affairs has documented elevated mesothelioma rates among Navy veterans who served aboard ships built before asbestos was phased out of military construction. For veterans exploring both treatment options and legal compensation, the veterans resource page provides specific guidance on VA benefits and claims processes.
What Should Patients and Families Do Next?
A mesothelioma diagnosis moves fast. The disease progresses quickly, and treatment windows can close. But moving fast doesn't mean moving without information.
The single most important step any newly diagnosed patient can take is seeking evaluation at a high-volume mesothelioma center before committing to a treatment plan. According to published outcomes data from centers like MSKCC and MD Anderson, patients treated at specialized programs consistently show better outcomes than those treated at general oncology practices, partly because of access to clinical trials, partly because of surgical volume and expertise.
Second, patients and families should understand that the legal and financial dimensions of a mesothelioma diagnosis are inseparable from the treatment decisions. Asbestos trust funds, established by bankrupt asbestos manufacturers, hold more than $30 billion in reserves for eligible claimants. Accessing those funds requires identifying specific exposure sources, often from decades-old employment records. The trust fund checker tool can help families determine whether a claim may be possible based on work history.
Statutes of limitations for mesothelioma claims vary by state and generally run from one to three years from the date of diagnosis. Missing that window permanently forecloses compensation options that can cover treatment costs, lost income, and family support. The statute of limitations tool provides state-by-state guidance, and connecting with a specialized attorney through the mesothelioma lawyer directory ensures that legal options are preserved while treatment proceeds.
From an occupational health perspective, I've seen too many families focus entirely on the medical side in the first weeks after diagnosis, only to discover months later that their legal window had narrowed significantly. The two tracks, medical and legal, need to run in parallel.
The Research Pipeline: What's Coming Next
The treatment landscape in 2026 is more dynamic than it's been at any point in mesothelioma's clinical history. Multiple trials are examining neoadjuvant immunotherapy before surgery, combination regimens pairing checkpoint inhibitors with anti-VEGF agents, and CAR-T cell therapies targeting mesothelin, a protein highly expressed on mesothelioma cells.
The Journal of Thoracic Oncology has published several analyses examining how tumor mutational burden and PD-L1 expression levels predict immunotherapy response in mesothelioma patients, with the goal of identifying which patients are most likely to benefit from checkpoint inhibition before surgery. That kind of biomarker-driven patient selection is the direction the field is moving.
Workers in these industries who developed mesothelioma after years of occupational asbestos exposure are the beneficiaries of this research acceleration, even if the timeline feels agonizingly slow from a patient's perspective. The combination of improved surgical techniques, validated immunotherapy regimens, and emerging targeted agents is genuinely expanding what's possible.
Carlos Medina's story isn't a guarantee of what any individual patient will experience. But it's a signal of where the field is heading: toward more flexibility, more personalization, and more willingness to challenge the treatment sequences that have defined mesothelioma care for a generation.
!Older patient and younger family member review treatment documents by golden window light
Frequently Asked Questions
What is the current standard of care for malignant pleural mesothelioma in 2026?
The current standard of care for unresectable malignant pleural mesothelioma is nivolumab plus ipilimumab, following FDA approval based on the CheckMate 743 trial, which showed median overall survival of 18.1 months versus 14.1 months for chemotherapy. For surgical candidates, treatment planning involves a multidisciplinary evaluation to determine whether pleurectomy/decortication or extrapleural pneumonectomy is appropriate, according to major cancer centers including MSKCC and MD Anderson.
What is the difference between pleurectomy/decortication and extrapleural pneumonectomy?
Pleurectomy/decortication (P/D) removes the tumor-laden pleural lining while preserving the lung. Extrapleural pneumonectomy (EPP) removes the entire affected lung along with surrounding structures. Research published in peer-reviewed oncology journals shows P/D carries roughly half the perioperative mortality of EPP, while achieving comparable survival in appropriately selected patients. The choice depends on tumor extent, patient fitness, and institutional expertise.
How does immunotherapy work for mesothelioma patients?
Nivolumab and ipilimumab are checkpoint inhibitors that block PD-1 and CTLA-4 signaling pathways, removing the molecular brakes that mesothelioma tumors use to evade immune detection. According to NIH-published research on immunotherapy advances, this dual blockade produces durable responses in a subset of patients, particularly those with non-epithelioid histology. The FDA approved this combination in 2020 based on survival data from the CheckMate 743 trial.
What is HIPEC and when is it used for mesothelioma?
HIPEC stands for hyperthermic intraperitoneal chemotherapy, a procedure delivered directly into the abdominal cavity during cytoreductive surgery for peritoneal mesothelioma. Research published in the Journal of Clinical Oncology found median survival exceeding five years in patients achieving complete cytoreduction with HIPEC, making it the most favorable survival outcome in the mesothelioma treatment landscape. It is reserved for eligible patients with peritoneal disease who can tolerate major surgery.
Can mesothelioma patients access clinical trials in 2026?
Yes. Multiple active trials are examining neoadjuvant immunotherapy before surgery, CAR-T cell therapies targeting mesothelin, and combination regimens pairing checkpoint inhibitors with anti-VEGF agents like bevacizumab. High-volume mesothelioma centers including MD Anderson and MSKCC offer trial access as part of their standard evaluation process. Patients should request clinical trial screening at their first specialist consultation, as eligibility windows can be time-sensitive.
Does occupational asbestos exposure affect treatment eligibility or outcomes?
Occupational exposure history doesn't directly affect treatment eligibility, but it's critical for legal compensation purposes. Identifying specific asbestos-containing products and job sites from employment records can support claims against asbestos trust funds, which hold more than $30 billion for eligible claimants. From an occupational health perspective, workers in shipbuilding, insulation, and construction trades carry the highest historical exposure burden and should pursue both specialized medical care and legal consultation simultaneously.
How important is it to seek a second opinion after a mesothelioma diagnosis?
Extremely important. Published outcomes data consistently shows better survival for patients treated at high-volume mesothelioma specialty centers compared to general oncology practices. Carlos Medina's case illustrates how a second opinion can change not just the treatment plan but the type of surgery offered. Major centers like MSKCC and MD Anderson recommend multidisciplinary tumor board review before any treatment decision, and a second opinion may reveal clinical trial options unavailable at smaller facilities.
This article is for informational purposes only and does not constitute medical advice. Consult your healthcare provider for guidance specific to your situation.
Comments (7)
— Anna Jackson
— Anna Jackson
The 18.1-month survival with nivolumab/ipilimumab is encouraging, but I'd add that the CheckMate 743 trial specifically showed this benefit in treatment-naïve patients. What's interesting is how this flips the traditional approach — my late father went through EPP followed by chemo back in 2019 at Johns Hopkins, and his oncologist said surgery first was standard then. The shift toward immunotherapy upfront plus lung-sparing pleurectomy/decortication makes sense given the lower perioperative mortality rates you mention. One thing the article could've emphasized more: patients need to ask about PD-L1 expression testing before starting immuno, since response rates vary significantly. Also, timing matters — if someone's diagnosed now, getting into a high-volume center quickly is critical to see if they're a candidate for sequencing before the disease progresses too far.
My dad was diagnosed with pleural mesothelioma back in 2018, and they went straight to surgery at Johns Hopkins. Wish they'd had this information about doing immunotherapy first because his recovery was brutal. The nivolumab/ipilimumab combo didn't even exist for us then, or at least nobody mentioned it. He made it about 16 months total. Reading that the lung-sparing procedure has lower mortality rates now makes me wish we'd known to push for that instead of the more aggressive surgery they recommended. If anyone's facing this decision right now, definitely get that second opinion at a high-volume center like they're saying. Don't just accept what the first doctor tells you.